Ablynx: Publication in Accordance With Article 14 of the Belgian Law
of 2 May 2007 Regarding the Publication of Major Shareholdings (the
GHENT, BELGIUM -- (Marketwire) -- 10/23/12 -- Ablynx (EURONEXT
BRUSSELS: ABLX) today announced, in accordance with Article 14 of the
Belgian Law of 2 May 2007 regarding the publication of major
shareholdings in issuers whose securities are admitted to trading on
a regulated market (the "Transparency Law"), that it received a
notification of shareholdings from Sofinnova Partners SAS and Gilde
Europe Food & Agribusiness Fund BV.
Sofinnova Partners SAS has dropped below the 15% threshold and Gilde
Europe Food & Agribusiness Fund BV has dropped below the 3%
Full versions of all transparency notifications are available on the
website of Ablynx, section Investors.
Ablynx is a biopharmaceutical company engaged in the
discovery and development of Nanobodies(R), a novel class of
therapeutic proteins based on single-domain antibody fragments, for a
range of serious human diseases, including inflammation, haematology,
oncology and pulmonary disease. Today, the Company has approximately
25 programmes in the pipeline and seven Nanobodies at clinical
development stage. Ablynx has ongoing research collaborations and
significant partnerships with major pharmaceutical companies
including Boehringer Ingelheim, Merck KGaA, Novartis and Merck & Co.
The Company is headquartered in Ghent, Belgium. More information can
be found on www.ablynx.com.
pdf version of the press release :
For more information, please contact
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
Follow us on Twitter @AblynxABLX
t: +44 207 920 2330
Press spacebar to pause and continue. Press esc to stop.